Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhenlubris Pharmaceuticals Co FCF Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhenlubris Pharmaceuticals Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shenzhenlubris Pharmaceuticals Co FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shenzhenlubris Pharmaceuticals Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Shenzhenlubris Pharmaceuticals Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhenlubris Pharmaceuticals Co (SZSE:002294) has a FCF Margin % of -1.51% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Shenzhenlubris Pharmaceuticals Co and its competitors. Over the past decade, Shenzhenlubris Pharmaceuticals Co's FCF Margin % has ranged from 0.73 to 31.04. According to the industry distribution chart, Shenzhenlubris Pharmaceuticals Co ranks #533 out of 962 companies in the Drug Manufacturers industry, placing it in the top 55.4%.
Is Shenzhenlubris Pharmaceuticals Co's FCF Margin % too high?
Shenzhenlubris Pharmaceuticals Co's current FCF Margin % is -1.51%. Over the past 10 years, this metric has ranged from a low of 0.73 to a high of 31.04. Based on the distribution chart, Shenzhenlubris Pharmaceuticals Co ranks #533 out of 962 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Shenzhenlubris Pharmaceuticals Co has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shenzhenlubris Pharmaceuticals Co's FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shenzhenlubris Pharmaceuticals Co ranks #533 out of 962 companies for FCF Margin %. This places Shenzhenlubris Pharmaceuticals Co in the lower half of its industry. The industry median FCF Margin % is 2.51. Historically, Shenzhenlubris Pharmaceuticals Co's own FCF Margin % has ranged from 0.73 to 31.04 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Shenzhenlubris Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shenzhenlubris Pharmaceuticals Co's current FCF Margin % is -1.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhenlubris Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Shenzhenlubris Pharmaceuticals Co (SZSE:002294) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥44.01, compared to a current price of ¥33.85 — trading 23.1% below its estimated fair value. The current FCF Margin % is -1.51%. Shenzhenlubris Pharmaceuticals Co's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Shenzhenlubris Pharmaceuticals Co (SZSE:002294), the current FCF Margin % is -1.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Overvalued in 2026?
Based on GuruFocus' analysis, Shenzhenlubris Pharmaceuticals Co stock appears to be undervalued.
The current stock price of ¥33.85 is trading 23.1% below its estimated GF Value™ of ¥44.01.
GuruFocus considers Shenzhenlubris Pharmaceuticals Co to be Modestly Undervalued.
Key valuation signals for SZSE:002294:
FCF Margin %: -1.51%
GF Value™: ¥44.01 vs. price of ¥33.85 (23.1% below fair value)
No single metric tells the full story. See the SZSE:002294 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalosporins, and bone resorption inhibitors. Its products mainly focus on the areas of cardio-cerebral vascular disease, diabetes, complications, anti-tumor, and orthopedics. Its business lines include high-end chemical drugs, biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other countries and regions.
82GF Score
Get the complete analysis for SZSE:002294
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:002294 has been successfully added to your 
